Organic Chemistry TRIZ Cases

This case controls DBC at 2–11 wt% in TACT coatings to improve surface appearance and avoid pinholes or sagging.

This case uses amphiphilic quinolinium-drug nanofibers to target mitochondria, boost phototoxicity, and limit rapid tumor clearance.

Suzuki coupling, stereoselective oxidation, and staged crystallization reduce impurities, waste, and catalyst use in PDE4B production.

Energy-level separation in N/P doped charge generation layers limits reverse transfer and supports efficiency and service life.

This case uses ionizable lipid nanoparticles to encapsulate circular RNA, supporting cellular uptake without genomic integration.

Dynamic crosslinkers compatibilize immiscible plastic mixtures while preserving reprocessability.

Substituted naphthyl compounds selectively inhibit p38α to alleviate inflammatory symptoms while preserving counterregulatory functions.

This case uses non-catalytic compounds to selectively inhibit p38α MAPK while preserving other isoforms and counter-regulatory responses.

This case develops UBR-box ligands that inhibit substrate binding and modulate protein degradation in UBR-related diseases.

This case uses single-dose baloxavir marboxil to reduce index-patient infectivity and limit influenza virus spread.

Redshifted photoinitiators enable low-odor LED curing with less oxygen inhibition.

Isophthalate and epoxy ester plasticizers improve PVC strength and resist migration.

This case uses crystalline Rucaparib salt forms to balance stability, dissolution, drug loading, and manufacturability.

A spirocyclic catalyst supports mild epoxide–CO2 cycloaddition with high selectivity, stability, and longer service life.

This case uses PEG 400, hydrogenated castor oil, and surfactants to solubilize ivacaftor for stable, easier oral dosing.

Replace complex amine analysis with visual, irreversible detection in a water-impermeable matrix.

This case uses keto oxime ester structures to combine 300–450 nm absorption, photopolymerization, and thermal stability.

Inkjet-ready OLED compounds lower voltage and improve device lifetime.

This case develops nitrogen-containing heterocycles as DHODH inhibitors to address weak anti-tumor activity and drug resistance.

This case replaces hazardous liquid acids with heterogeneous solid catalysts for safer, scalable CBD conversion toward Δ8-THC.

This case uses caffeine-tannic acid complexes in emulsions to slow absorption, extend effects, and reduce jitteriness from rapid release.

This case uses formula-based fused polycyclic compounds in OLED layers to improve luminous efficiency through delayed fluorescence.

This case develops selective imidazopyrazines with membrane permeability and metabolic stability for sustained NR2B therapy.

Propenimine compounds enable stable toner softening while limiting orange coloration.

Diquaternary SDAs with rigid cyclic groups address small-pore limits by forming zeolites suited to larger hydrocarbon molecules.

Low-IDGE isosorbide epoxy pre-polymers reduce mutagenic potential.

See how controlled pH and molecular weight stabilize aqueous multi-aziridine crosslinkers for room-temperature, low-VOC coating systems.

This route combines copper-catalyzed C–N coupling, Friedel-Crafts alkylation, and cyclization to reduce time and cost.

This catalytic synthesis targets high-purity 5-(3-pyridyl)-2,2′-bithiophene with 75–80% conversion and minimal contamination.

This case targets CpLDH with NSC158011 and NSC10447 to address weak treatment efficacy in vulnerable patients.

Gas purging, static replacement, and concentration-controlled phenol washing reduce water, time, and phenol use before BPA synthesis.

Aziridine crosslinkers support water-based polymer curing with lower genotoxicity.

This case uses bridged-bicyclic thiolactone ROP to balance crystallinity, thermal stability, mechanical strength, and full recyclability.

Variable plasma levels from oral psilocybin are addressed with transdermal and nasal formulations that bypass gastrointestinal metabolism.

This case uses imidazopyridinyl pyrimidin-2-amine structures to balance kinase efficacy and specificity across FLT3 and CDKs.

Electrophilic inhibitor compounds form covalent bonds with SUMO E1 to address aberrant modification linked to cancer.

This case uses tailored diglycolamides to selectively recover rare earths from acidic streams with less third-phase formation and acid use.

SAR-based Formula I compounds target mutated BCL-2 while supporting cancer-cell apoptosis and limiting off-target effects.

Phenolic lipid HDO produces dense renewable diesel with lower cloud points.

This case develops structured RAS inhibitors that block GTPase activity and address resistance caused by mutant KRAS in cancer treatment.

A donor-bridge-acceptor EO polymer targets low O-band absorption and strong electro-optic response across 1260–1625 nm.

Substituted pyridinium compounds react with hydrogen peroxide to generate organic peroxy acids and enhance bleaching performance.

Defined compound structures and pharmaceutical compositions selectively inhibit PI3K-alpha H1047R mutations for cancer therapy.

This case uses quaternary ammonium compounds to enter TRPV1 channels and selectively inhibit itch- and pain-sensing neurons.

This case replaces harsh N-demethylation with an oripavine-based route for shorter buprenorphine production and less toxic waste.

This case uses aqueous maceration, controlled heating, and heat exchangers to extract high-purity nicotine with less energy and waste.

P450 enzymes convert miltiradiene into oxygenated diterpenoids, increasing triptophenolide and triptonide yields.

Amino alcohol modification targets tyrosinase while improving epidermal safety.

FAP inhibitor compounds target tumor uptake and retention for precise imaging.

An iodine- and cyclic-ether-containing onium salt improves acid diffusion control, sensitivity, resolution, and collapse resistance in small patterns.

Specific functional groups in the nucleating agent balance crystallization rate with shrinkage consistency.

Sulfonated quenchers increase hydrophilicity and cellular uptake, resolving the trade-off between detection sensitivity and probe stability.

Copolymerizable benzotriazole compounds integrate into ophthalmic lens matrices to block ultraviolet and blue light, preventing absorber leaching.

Benzofuranone derivatives prevent yellowing in polycarbonate under heat and light exposure while maintaining transparency.

Compounds targeting the RAS Switch I/II pocket inhibit downstream signaling in KRAS mutant cells.

Substituted branched ketones replicate natural orris odor while avoiding expensive stereoselective synthesis costs.

Fluorenone derivatives enable reversible two-electron transfer without metal catalysts, resolving high dehydrogenation energy barriers.

Liquid-liquid extraction with a lipophilic solvent removes resin acids from knotwood extract, achieving over 90% purity of lignans and flavonoids.

A ceramic printing ink composition containing silver nanoparticles and silica nanotubes provides stable pattern deposition on coating layers.

Modifying the chemical structure of a piperidine derivative enhances solubility and half-life for effective orexin receptor antagonism.

Thiourea reacts with 2-aminobenzophenone to form substituted quinazolines, bypassing complex multi-step processes that reduce yield.

A biphasic mixture process eliminates difficult filtration of fine particles, cutting processing time from eleven days to one day while maintaining high purity.

An emission-auxiliary layer using a high T1 energy carbazole compound blocks exciton transport to resolve charge imbalance and improve luminescence efficiency.

Benzobisnaphthofuran derivatives form high-crystallinity films that resolve low carrier mobility in solution-processed transistors.

Polycyclic compounds inhibit plasma kallikrein, reducing bradykinin generation and swelling attacks in hereditary angioedema.

Non-aromatic cyclic ester solvents optimize viscosity and surface tension to achieve homogeneous organic semiconductor layers while simplifying process control.

A palladium catalyst and copper co-catalyst facilitate annulation between monohalogenated dithiophene and internal alkyne.

Cbl-b inhibitor compounds combine with cancer vaccines or oncolytic viruses to overcome limited efficacy against visceral metastases.

Short-chain cationic lipids reduce liver toxicity while maintaining high siRNA delivery efficacy in vivo.

Alpha-7 nicotinic receptor agonists improve cognitive deficits and reduce negative symptoms in schizophrenia and Alzheimer's disease.

Transesterification of epoxidized soyate with unhindered polyols using a metallic hydroxide and titanate catalyst system.

A sulfonium compound structures resist composition to control acid diffusion during lithography exposure.

Segmented dye structures with flexible linkers reduce steric hindrance while maintaining spectral properties.

Novel diarylalkylamine compounds resolve poor pharmacokinetic properties and lack of selectivity in current REV-ERB modulators.

A resist composition uses a specific compound to produce patterns with enhanced CD uniformity.

Modified E3 ligase binding units reduce off-target toxicity while maintaining degradation efficacy.

Non-planar carbazole olefin structures confine triplet excitons to resolve efficiency roll-off while extending device lifetime.

Heteroaryl disulfide compounds shift hemoglobin equilibrium toward the R-state, increasing oxygen-binding affinity while preventing red blood cell sickling.

Formula I sulfamoyl-arylamides reduce toxicity and mutagenicity while maintaining antiviral efficacy against hepatitis B.

Novel quinoline cyclohexyl amide compounds inhibit mutated androgen receptors to overcome treatment resistance in castration-resistant prostate cancer.

Host-guest stilbene derivatives achieve blue emission color purity and device lifetime by resolving trade-offs between reliability and manufacturing complexity.

Segmenting synthesis into three steps yields stable aliphatic sulfonyl azide anhydrides with uniform dispersion for multilayer film tie layers.

Synthesizing Clopidogrel using kinetic resolution with camphor sulfonic acid.

Dual host compounds in the light emitting layer resolve trade-offs between charge mobility and device lifetime to improve overall OLED reliability.

Reaction products of diamines and bisanhydrides function as leveling agents that reduce thickness variation between substrate surfaces and apertures.

Local quality design achieves selective Btk inhibition to minimize off-target effects in autoimmune disease treatment.

Specific organic compounds with nitrogen rings and transition metal complexes in OLEDs address insufficient color saturation.

Segmented synthesis of 1,3,5-triazine scaffolds resolves isoform specificity and synthesis complexity.

Dicarboxylate-capped estolide compounds synthesize renewable fatty acids into biodegradable lubricant fluids that replace toxic petroleum oils.

Pyrimidine compounds target the MMP-9 hemopexin domain to inhibit cancer cell migration while preserving protease catalytic activity.

Aromatic compounds with bridged amino groups serve as hole transport materials in organic light-emitting diodes.

Beta zeolite catalyst overcomes low yields and side-product formation in TMTHF production by enabling high-purity cyclization.

A bis-resorcinyl triazine process uses aqueous suspension to improve filtration speed.

Protonated tertiary amine groups enable transdermal delivery, bypassing first-pass metabolism and reducing gastrointestinal side effects.